soul trial oral semaglutide cardiovascular outcomes 2024 nejm 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM FLOWing with the SemagluTIDE —

Adding more liquid makes the solution more dilute, which increases the draw volume for the same target amount

It has been reported that GLP-1 can improve energy efficiency by increasing glucose assimilation in the heart, which promote cardiac performance [60, 61]

Ulvi H, Aygul R, Demir R

Acute pancreatitis was reported in all 11 studies, with ARD values typically below 0.3% and overall event rates below 1%, suggesting no meaningful increase in risk compared with placebo

Hu J, Zhou GW, Wang N, Wang YJ

The thickness of subcutaneous fat in this region naturally varies by patient, but remains generally adequate for most body types seeking semaglutide therapy